Skip to main content

Table 4 Case-control comparison of NAT1 genotypes

From: Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study

 

Controls(N = 426)

Cases (N = 545)

   

NAT1 Genotype

n

%

n

%

OR

CI

p

NAT1*4/*4

211

50.8

268

49.7

1

  

NAT1*10/*11A

4

1.0

5

0.9

1.03

0.26-4.35

0.967

NAT1*10/*10

14

3.4

22

4.1

1.22

0.61-2.52

0.583

NAT1*4/*3

13

3.1

23

4.3

1.50

0.74-3.14

0.271

NAT1*4/*14A or *10/*14B

13

3.1

19

3.5

1.25

0.60-2.66

0.552

NAT1*10/*14A

4

1.0

6

1.1

1.12

0.31-4.45

0.863

NAT1*4/*10

138

33.3

165

30.6

0.94

0.70-1.26

0.677

NAT1*4/*11A or *3/*11B

13

3.1

21

3.9

1.21

0.59-2.55

0.607

NAT1*10/*15

0

0.0

1

0.2

--

--

--

NAT1*11A/*14A

0

0.0

1

0.2

--

--

--

NAT1*3/*10

2

0.5

4

0.7

1.65

0.32-12.10

0.567

NAT1*3/*14A

0

0.0

1

0.2

--

--

--

NAT1*4/*11B

0

0.0

1

0.2

--

--

--

NAT1*4/*15

3

0.7

2

0.4

0.37

0.05-2.39

0.298

Missing

11

 

6

    
  1. Logistic regression analysis of individual NAT1 genotypes, adjusted for age. NAT1*4/*4 used as reference. Overall chi-squared p = 0.99 (likelihood ratio test). Genotypes with 10 or less counts in either group (case or control) were not included in overall test of significance. OR = odds ratio, CI = 95% confidence intervals for ORs, p = p-value